Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Conditions
Colon | Rectum
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This is a phase II, open-label, non-randomized study in subjects with histologically confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who have not received prior systemic therapy for metastatic disease.
- Trial withAcademic GI Cancer Consortium (AGICC)
- Start Date01/12/2022
- End Date09/01/2022
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Anamika Katoch, MD
- Andrea Brennan
- Andrea Martelli
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Khanh Nguyen, MD
- Kristen Hoxie
- M. Sung Lee, MD
- Madeline Santiago
- Marianne Davies, NP, DNP, MSN, BSN
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Pamela Kunz, MD
- Pawan Karanam, MD
- Robert Legare, MD
- Sara Anastasio, RN
- Sarah Carlson
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Victor Chang, MD
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Last Updated01/13/2022
- Study HIC#2000026787